

Thionordazepam: strong intermolecular
N—H···N hydrogen-bonded chainsR. S. Narasegowda,^a T. Vijay,^b
H. S. Yathirajan,^a P. Nagaraja,^a
T. Narasimhamurthy^c and
R. S. Rathore^{d*}^aDepartment of Studies in Chemistry, University of Mysore, Manasagangotri, Mysore 570 006, India, ^bSolid State and Structural Chemistry Unit, Indian Institute of Science, Bangalore 560 012, India, ^cBioinformatics Center, Indian Institute of Science, Bangalore 560 012, India, and ^dOriental Organization of Molecular & Structural Biology, 204 Agarwal Bhavan, Malleshwaram, Bangalore 560 055, IndiaCorrespondence e-mail:
ravindranath_rathore@yahoo.com


Key indicators

Single-crystal X-ray study
T = 293 K
Mean $\sigma(\text{C}—\text{C})$ = 0.008 Å
R factor = 0.062
wR factor = 0.142
Data-to-parameter ratio = 17.3For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.


In the title compound, 7-chloro-1,3-dihydro-5-phenyl-2*H*-1,4-benzodiazepine-2-thione, $\text{C}_{15}\text{H}_{11}\text{ClN}_2\text{S}$, the central seven-membered diazepinethione ring adopts a boat conformation. The dihedral angle between the planes of the aromatic rings is $63.7(1)^\circ$. The crystal packing is determined by strong N—H···N hydrogen bonds, generating a one-dimensional chain along [001].

Comment


Benzodiazepines represent a very important class of compounds, collectively referred to as anxiolytics, which act as indirect agonists by binding to the GABA-A receptor, a primary inhibitory neurotransmitter in the central nervous system (Williams *et al.*, 2002). The title compound, 7-chloro-1,3-dihydro-5-phenyl-2*H*-1,4-benzodiazepine-2-thione, (I), commercially known as thionordazepam, is one of the derivatives of benzodiazepine, which is used for the preparation of anxiolytic alprazolam (Wang & De Vane, 2003).



The structure of (I) is illustrated in Fig. 1. In (I), the planes defined by aromatic rings C1–C6 and C10–C15 form a dihedral angle of $63.7(1)^\circ$. The central seven-membered diazepinethione ring (atoms C4/C5/C7–C9/N1/N2) adopts a boat conformation. The boat conformation is predominantly observed for the seven-membered ring of benzodiazepine and its derivatives, even with different double-bond positions and widely differing substituents (Walkinshaw, 1985; Torres *et al.*, 2005). The internal torsion angles of the ring are shown in Fig. 1. The Cremer and Pople puckering parameters (Cremer & Pople, 1975) are $q_2 = 0.817(5)$ Å, $q_3 = 0.245(5)$ Å, $\varphi_2 = 26.5(3)^\circ$ and $\varphi_3 = 130(1)^\circ$; and the total puckering amplitude $Q_T = 0.853(5)$ Å. The asymmetry parameter, measured as the root-mean-square of the sum of the torsion angles, related by a mirror plane (Duax *et al.*, 1976), passing through atom C8 and bisecting the C4–C5 bond, is marginal, *i.e.* $\Delta C_s = 3.2(5)^\circ$, indicating a near ideal boat conformation of the ring. The overall molecular conformation is additionally described by the rotation about the C9–C10 bond; the torsion angle C5–C9–C10–C15 is $39.1(6)^\circ$.

**Figure 1**

A view of (I), showing 20% probability displacement ellipsoids and the atom-numbering scheme. The numerical figures refer to the internal torsion angles ($^{\circ}$) of the central diazepinethione ring in a boat conformation (s.u. values lie in the range 0.5–0.6 $^{\circ}$). H atoms are shown as small spheres of arbitrary radii.

**Figure 2**

Part of the crystal packing of (I), showing N—H...N hydrogen-bonded (dashed lines) chains along [001]. The atom labelled with an asterisk (*) is at the symmetry position ($x, \frac{3}{2} - y, z - \frac{1}{2}$). Color key: C black, N blue, S yellow and Cl green.

The molecules in the crystal structure are linked by strong intermolecular N—H...N hydrogen bonds (Table 1). Strong N—H...N bonds, presumably low-barrier hydrogen bonds, have been generally observed as intramolecular (Hilbert & Emsley, 1990; Perrin & Nielson, 1997). The N—H...N hydrogen bonds link symmetry-related molecules into a chain along [001], as shown in Fig. 2. In contrast to the similar structures of halogen derivatives of benzodiazepine reported previously (Prasanna & Guru Row, 2000), the molecular assembly in the present case does not display any direction-specific halogen or aromatic interactions.

Experimental

The title compound was obtained from Lake Chemicals, Bangalore. Single crystals suitable for X-ray diffraction were grown by slow evaporation of an ethyl acetate solution.

Crystal data

$C_{15}H_{11}ClN_2S$
 $M_r = 286.77$
 Orthorhombic, $Pnc2$
 $a = 9.993$ (2) Å
 $b = 14.223$ (3) Å
 $c = 10.175$ (2) Å
 $V = 1446.2$ (5) Å³
 $Z = 4$
 $D_x = 1.317$ Mg m⁻³

Mo $K\alpha$ radiation
 Cell parameters from 1456 reflections
 $\theta = 5\text{--}35^{\circ}$
 $\mu = 0.40$ mm⁻¹
 $T = 293$ (2) K
 Thin plate, colourless
 $0.5 \times 0.3 \times 0.08$ mm

Data collection

Bruker SMART CCD area-detector diffractometer
 φ and ω scans
 Absorption correction: multi-scan (SADABS; Sheldrick, 1996)
 $T_{\min} = 0.865$, $T_{\max} = 0.972$
 10960 measured reflections

3021 independent reflections
 1505 reflections with $I > 2\sigma(I)$
 $R_{\text{int}} = 0.057$
 $\theta_{\max} = 27.4^{\circ}$
 $h = -11 \rightarrow 12$
 $k = -18 \rightarrow 17$
 $l = -13 \rightarrow 13$

Refinement

Refinement on F^2
 $R[F^2 > 2\sigma(F^2)] = 0.062$
 $wR(F^2) = 0.142$
 $S = 1.00$
 3021 reflections
 175 parameters
 H atoms treated by a mixture of independent and constrained refinement

$w = 1/[\sigma^2(F_o^2) + (0.0619P)^2]$
 where $P = (F_o^2 + 2F_c^2)/3$
 $(\Delta/\sigma)_{\max} = 0.001$
 $\Delta\rho_{\max} = 0.25$ e Å⁻³
 $\Delta\rho_{\min} = -0.15$ e Å⁻³
 Absolute structure: Flack (1983), 1358 Friedel pairs
 Flack parameter: 0.42 (11)

Table 1

Hydrogen-bond geometry (Å, $^{\circ}$).

$D\text{—}H\cdots A$	$D\text{—}H$	$H\cdots A$	$D\cdots A$	$D\text{—}H\cdots A$
$N1\text{—}H1\cdots N2^i$	0.88 (1)	1.95 (3)	2.827 (5)	177 (3)

Symmetry code: (i) $x, -y + \frac{3}{2}, z - \frac{1}{2}$.

Atom H1 was located in a difference Fourier map and was refined with an N—H distance restraint of 0.88 (1) Å and with $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{N})$. All other H atoms were positioned geometrically and refined as riding on their carrier atoms, with aromatic C—H = 0.93 Å, methylene C—H = 0.97 Å and $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$. The authenticity of the high value of Flack (1983) parameter [0.4 (1)] was evaluated by refining inversion twin contributions. This yielded the same, 0.4 (1) value of the batch scale factor, indicating that the structure could be a

mixture of inversion twin components having contributions of 0.4 and 0.6. Since treatment of the inversion twin in this way did not significantly improve the *R* values and other indicators of the refinement, the present structure is reported without such treatment.

Data collection: *SMART* (Bruker, 1998); cell refinement: *SAINT-Plus* (Bruker, 2001); data reduction: *SAINT-Plus*; program(s) used to solve structure: *SHELXTL* (Bruker, 2000); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEP3* (Farrugia, 1997) and *PLATON* (Spek, 2003); software used to prepare material for publication: *WinGX* (Farrugia, 1999) and *PARST* (Nardelli, 1995).

Thanks are expressed to Lake Chemicals, Bangalore, India, for providing the sample. We thank Professor T. N. Guru Row for providing access to the CCD facility set up under the IRHPA–DST program.

References

- Bruker (1998). *SMART*. Version 5.628. Bruker AXS Inc., Madison, Wisconsin, USA.
- Bruker (2000). *SHELXTL*. Version 6.1. Bruker AXS Inc., Madison, Wisconsin, USA.
- Bruker (2001). *SAINT-Plus*. Version 6.02a. Bruker AXS Inc., Madison, Wisconsin, USA.
- Cremer, D. & Pople, J. A. (1975). *J. Am. Chem. Soc.* **97**, 1354–1358.
- Duax, W. L., Weeks, C. M. & Rohrer, D. C. (1976). In *Topics in Stereochemistry*, edited by E. L. Eliel & N. L. Allinger, Vol. 9, pp. 271–383. New York: Interscience.
- Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.
- Farrugia, L. J. (1999). *J. Appl. Cryst.* **32**, 837–838.
- Flack, H. D. (1983). *Acta Cryst.* **A39**, 876–881.
- Hilbert, F. & Emsley, J. (1990). *Adv. Phys. Org. Chem.* **26**, 255–379.
- Nardelli, M. J. (1995). *J. Appl. Cryst.* **28**, 659.
- Perrin, C. L. & Nielson, J. B. (1997). *Annu. Rev. Phys. Chem.* **48**, 511–544.
- Prasanna, M. D. & Guru Row, T. N. (2000). *CrystEngComm*, **2**, 134–138.
- Sheldrick, G. M. (1996). *SADABS*. University of Göttingen, Germany.
- Sheldrick, G. M. (1997). *SHELXL97*. University of Göttingen, Germany.
- Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.
- Torres, H., Insuasty, B., Cobo, J., Low, J. N. & Glidewell, C. (2005). *Acta Cryst.* **C61**, o404–o407.
- Walkinshaw, M. D. (1985). *Acta Cryst.* **C41**, 1253–1255.
- Wang, J. S. & De Vane, C. L. (2003). *Psychopharmacol. Bull.* **37**, 10–29.
- Williams, D. A., Lemke, T. A. & Foye, W. O. (2002). *Foye's Principles of Medicinal Chemistry*, Vth ed. Hagerstown: Lippincott Williams & Wilkins.